-+ 0.00%
-+ 0.00%
-+ 0.00%

Anavex delays filing quarterly report for March 31, 2026 quarter

PUBT·05/11/2026 20:33:31
Listen to the news
Anavex delays filing quarterly report for March 31, 2026 quarter
  • Anavex Life Sciences filed Form 12b-25 to delay its quarterly report on Form 10-Q for period ended March 31, 2026, missing prescribed May 11, 2026 due date.
  • Delay tied to ongoing review of matters related to termination of former CEO Christopher Missling on April 30, 2026, with Terrie Kellmeyer appointed interim CEO on May 4, 2026.
  • Filing expected once special committee completes its review and interim CEO finishes review required for certification.
  • Notification indicated no anticipated significant change in results of operations versus corresponding period last fiscal year.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anavex Life Sciences Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001731122-26-000702), on May 11, 2026, and is solely responsible for the information contained therein.